Infectious Disease Testing Market: Kalorama Information, a trusted source for healthcare market intelligence, released insights into the evolving global market for infectious disease testing through the In Vitro Diagnostics Business Outlook newsletter. Despite the decline in COVID-19 testing, the overall infectious disease diagnostics market remains robust, supported by sustained demand for non-COVID tests and the adoption of next-generation technologies across both laboratory and point-of-care (POC) settings.

With testing essential for diagnosing, monitoring, and containing a wide range of infections—from respiratory illnesses and bloodborne viruses to sepsis and gastrointestinal pathogens—the market continues to attract significant attention and investment. Kalorama’s latest report highlights a steady shift in growth drivers, with POC solutions, molecular platforms, and advanced immunoassays gaining ground.

“Infectious disease diagnostics continues to be one of the most innovative segments of the IVD industry,” said Daniel Granderson, Senior Editor of Kalorama Information. “New technologies are not only enhancing diagnostic speed and accuracy but are also reshaping where and how testing is performed—bringing more solutions to decentralized and resource-limited settings.”

Highlights from the article include:

• Strong global demand for lab-based immunoassays and molecular tests
• Continued innovation in syndromic panels, microfluidics, and cartridge-based POC platforms
• A growing share of the market shifting toward emerging regions, with Asia Pacific and other developing areas seeing increased diagnostic infrastructure and demand
• Major industry players—including Roche, Abbott, Danaher, and QIAGEN—introducing new products to address unmet needs in STIs, sepsis, and respiratory diseases

The report also profiles emerging innovators bringing AI-powered diagnostics, rapid sepsis panels, and cost-effective molecular tools to market, emphasizing the industry’s ongoing focus on speed, accuracy, and accessibility.